All In Biotech

Drug Trial Radar · NCT00152204

The Community Effectiveness of IPTi in Southern Tanzania

Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants

Last checked: Nov 20, 2026Latest source record: May 22, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 13,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

13,000

Planned (sponsor's estimate)

Start

Mar 2005

Primary completion

Dec 2007

Study completion Dec 2008

Sponsor

Lead sponsor
Swiss Tropical & Public Health InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ifakara Health Research and Development Centre; Ministry of Health, Tanzania; Hospital Clinic of Barcelona; London School of Hygiene and Tropical Medicine
First posted
Sep 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The safety and efficacy of Intermittent Preventive Treatment for malaria and anaemia control in Infants (IPTi) have already been documented in Southern Tanzania, affording an opportunity to gain operational experience in developing a strategy for the longer-term implementation of IPTi. Working in conjunction with national and district-based health authorities, a strategy will be developed to make IPTi available through routine health services and an effectiveness evaluation conducted. This will be based on the comparison of process and outcome indicators in areas with and without IPTi. Information on safety will be consolidated and the effect of IPTi on the rate of development of drug resistance explored. The acceptability and costs of implementing IPTi will be monitored and combined with assessments of effectiveness (in terms of morbidity and mortality) to assess the cost-effectiveness of IPTi.

Conditions

  • Malaria, Falciparum
  • Anemia

Interventions

  • Sulfadoxine-pyrimethamine used for IPTiDrug

    Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination

  • IPTiDrug

    Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mortality rate in children aged 2-11 months (estimated by birth history questioning)Time frame: Up to 12 months of age
  2. Incidence of severe adverse drug reactions following IPTi (as detected by spontaneous, passive reporting system)Time frame: All age groups, particular attention in under 2 year olds

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ifakara Health Research & Development Centre

    Dar es Salaam, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.